Korea FDA Moves To Elevate Patent-Approval Team To A Division
This article was originally published in PharmAsia News
As it implements provisions in the U.S.-South Korea FTA, KFDA is creating a division to oversee patent-approval issues, upgrading the status and manpower of a temporary task force team.
You may also be interested in...
SEOUL - Despite discontent among opposition parties in South Korea with the recently revised Free Trade Agreement with the U.S., Korea's generic drug makers are welcoming new supplementary agreements, which they say would give them a three-year grace period during which they could launch generic versions of patented products
SEOUL - South Korea's Ministry of Foreign Affairs and Trade unveiled the content of pharmaceutical and medical device provisions in its Free Trade Agreement with the EU, which was initialed by its Trade Minister Kim Jong-hoon and EU Trade Commissioner Catherine Ashton in Brussels Oct. 15
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.